Trial Profile

A phase 3 global study of Pridopidine in amyotrophic lateral sclerosis patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 15 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pridopidine (Primary)
Indications Amyotrophic lateral sclerosis
Focus Registrational; Therapeutic Use
Sponsors Prilenia Therapeutics

Most Recent Events

12 Mar 2024 According to a Prilenia Therapeutics media release, in January 2024 company had completed discussions with global regulatory agencies regarding the next stage of development of pridopidine for amyotrophic lateral sclerosis (ALS) and is planning for a single pivotal Phase 3 study.
24 Jan 2024 New trial record
19 Jan 2024 According to a Prilenia Therapeutics media release, company will present clinical data supporting a future Phase 3 study in amyotrophic lateral sclerosis (ALS) during the 14 Annual California ALS Research Summit in Los Angeles.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com